European Union: European Competition Law Newsletter – September 2015

Last Updated: September 7 2015
Article by Matthew Hall

Open to All; Small Business Obtains Interim Injunction to Restrain Alleged Abuse of Dominance

A self-described "small business" recently succeeded in obtaining an interim injunction (restraining an alleged abuse of dominance) in a UK court against the giant telecom provider Telefónica (trading in the UK under the name O2). This shows the continuing development of private competition law litigation in the UK (and EU generally), including outside the "follow-on" sphere, and its use even by SMEs.

The claimant in the case, Packet Media Limited (PML), provides telecommunication services and, in particular, services involving the sale or leasing of global system for mobile telecommunications (or GSM) Gateway equipment and the reselling of air time. This enables end customers to engage in single-user self-use of GSM Gateways. O2 is a mobile network operator (or MNO) in the UK.

On 5 June 2015, O2 sent a letter to PML's counsel in which it gave PML seven days' notice of the suspension of the services to the SIM cards (or subscriber identity module cards) that PML and its customers were using in gateways on the network and which O2 was aware of. The letter identified 2,045 SIM cards which O2 intended to disconnect. PML argued before the court that the action which O2 proposed to take would constitute an abuse of a dominant position contrary to the UK Competition Act 1988.

A GSM Gateway is not itself a phone but rather is installed as part of the user's switching equipment with the effect that when the user makes a call, or sends an SMS message, from a fixed phone line to a mobile phone number (known for short as "F2M traffic"), that call is diverted from the fixed line through the GSM Gateway connecting with the receiving mobile network via the air interface. The call or SMS then attracts a lower cost than if it had been made as a conventional fixed line communication to be terminated on a mobile network.

In considering the application for an injunction, the judge held that the relevant market is the wholesale provision of access to call and SMS text origination on mobile networks operating and serving customers within the UK market. PML's market is the retail provision of fixed-to-mobile calls and SMS text messages to end users.

The judge also found that there was an arguable case of alleged abuse of a dominant position in this market (call origination) and that the balance of convenience favoured the grant of interim relief so as to preserve the status quo pending trial.

Rare Excessive Pricing Case

On 6 August 2015, the UK Competition and Markets Authority (CMA) announced that it had sent a statement of objections (SO; preliminary statement of case) to Pfizer and Flynn Pharma alleging abuse of a dominant position under EU and UK competition law arising out of excessive and unfair pricing of a pharmaceutical product. This is therefore an unusual example of an EU regulator going after companies for excessive pricing.

Pfizer is the manufacturer of the drug in question (phenytoin sodium) and Flynn Pharma is a UK distributor. The SO concerns both the prices that Pfizer has charged to Flynn Pharma and the prices that Flynn Pharma has charged to its customers, since September 2012.

Prior to September 2012, Pfizer manufactured and sold phenytoin sodium capsules to UK wholesalers and pharmacies under the brand name Epanutin. Pfizer sold the UK distribution rights for Epanutin to Flynn Pharma, which de-branded (or genericised) the drug and started selling its version in September 2012. Pfizer continued to manufacture the drug, which it sold to Flynn at prices that were significantly higher than those at which it had previously sold Epanutin in the UK – between eight and 17 times Pfizer's historic prices. Flynn then sold the drug on to customers at prices which were between 25 and 27 times higher than those historically charged by Pfizer.

Prior to September 2012, the UK National Health Service (NHS) spent approximately £2.3 million on phenytoin sodium capsules annually. This spend (paid to Flynn and other suppliers of phenytoin sodium capsules) was just over £50 million in 2013 and over £40 million in 2014.

The CMA commented that this price increase was "very high" and "led to a big increase in the NHS drug bill". Assuming the parties are dominant, the issue is likely to be whether there was any justification for this, since on the face of it the September 2012 changes do seem likely to have produced excessive prices.

Although these types of cases are rare, it's interesting to note that the European Commission (EC) is currently investigating Gazprom for excessive pricing under EU competition law. It has alleged (in an SO of 22 April 2015) that the company has been pursuing an unfair pricingpolicy in five EU Member States, charging prices to wholesalers that are significantly higher compared to Gazprom's costs or to benchmark prices. These unfair prices allegedly result partly from Gazprom's price formulae that index gas prices in supply contracts to a basket of oil product prices and have unduly favoured Gazprom over its customers. The CMA will be applying similar principles and case law as are being used by the EC in the Gazprom investigation.

The Benefits of a Compliance Programme

As reported in our August 2015 European Competition Law Newsletter, a membership organisation of UK private consultant ophthalmologists, Consultant Eye Surgeons Partnership (CESP) Limited, has admitted breaching competition law and agreed to pay a fine. This was set at £500,000 but reduced to £382,500 since it co-operated with the CMA and also since it adopted a "comprehensive competition law compliance programme".

CESP Limited gained a 10% reduction for adopting the compliance programme and a further 15% discount for co-operating and admitting the infringement.

CESP Limited has accepted liability for a number of infringements during the period September 2008 to present, which include the following:

  • Recommending that its members refuse to accept lower fees offered by an insurer, and that they charge insured patients higher self-pay fees.
  • Circulating amongst its members detailed price lists for ophthalmic procedures, such as cataract surgery, to be used with insurers. These collectively set prices did not pass on lower local costs (such as cheaper hospital fees) and made it harder for insurers and patients to obtain lower prices.
  • Facilitating the sharing of consultants' future pricing and business intentions such as whether to sign up to a private hospital group's package price, which enabled members to align their responses.

CESP Limited did not have a competition compliance programme and the CMA welcomed the adoption of one as a "positive step" which "[sets] a good example for other organisations in the medical professions".

This reduction for adopting a compliance programme is in accordance with the CMA's fining guidelines, which state:

"... the CMA will consider carefully whether evidence presented of an undertaking's compliance activities in a particular case merits a discount from the penalty of up to 10 per cent. Thus, the mere existence of compliance activities will not be treated as a mitigating factor. However, in an individual case, evidence of adequate steps having been taken to achieve a clear and unambiguous commitment to competition law compliance throughout the organisation (from the top down) – together with appropriate steps relating to competition law risk identification, risk assessment, risk mitigation and review activities – will likely be treated as a mitigating factor. The business will need to demonstrate that the steps taken were appropriate to the size of the business concerned and its overall level of competition risk. It will also need to present evidence on the steps it took to review its compliance activities, and change them as appropriate, in light of the events that led to the investigation at hand ...".

This position remains very different from that still adopted by the EC, which it describes as:

"The mere existence of a compliance strategy will not be taken into consideration when setting the fine: the best reward for a good compliance strategy is not to infringe the law."

Compensation Schemes for Breaches of Competition Law in the UK

On 14 August 2015, the CMA published guidance on a new power to encourage competition law-breaking businesses voluntarily to pay compensation to victims.

Under the guidance, businesses setting up voluntary redress schemes can, in certain circumstances, receive a discount of up to 20% of any penalty imposed by the CMA for a breach of competition law.

The guidance provides details on how businesses can apply to the CMA for approval of a scheme, how it will consider such applications, the procedural framework for determining levels of compensation, and how schemes should operate.

The schemes do not prevent affected consumers or businesses from taking action through the courts for damages if they prefer.

The new power is part of a wider set of changes under the UK Consumer Rights Act 2015 (CRA) intended to make it easier, quicker and less costly for those who have suffered from breaches of competition law to obtain redress (and to improve the UK's position as a venue of choice for private competition law litigation in the EU). Other key changes include increasing the UK Competition Appeal Tribunal's (CAT's) role in competition private actions by, for example, introducing enhanced provisions on opt-out and opt-in collective actions in the CAT and providing for a fast-track procedure to enable simpler cases brought by small businesses to be resolved more quickly and at a lower cost.

Additional European competition law news coverage can be found in our news section.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Related Topics
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of

To Use you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions